BETAPREDICT
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Interferon beta-1b
Interferon alpha/beta receptor agonist
- Betaconnect Autoinjector
What it measured
Main measures
Compliance to therapy (%)
12 months
Persistence of therapy (Yes or No)
12 months
Overall adherence to therapy (Yes or No)
12 months
Quality of life (reported by participants)
Other measures (5)
Satisfaction with the BETACONNECT autoinjector, recorded by the patient questionnaire
Up to 24 months
Quality of life (reported by participants)Adherence to Betaferon treatment is associated with: depression, health related quality of life, coping mechanisms, self-management mechanisms, social support, fatigue, and cognition. (Yes or No)
Up to 24 months
Thinking and memoryFatigueMood and sleepQuality of life (reported by participants)Adherence to Betaferon treatment is associated with number of relapses (Yes or No)
12 months, 24 months
RelapsesQuality of life (reported by participants)Adherence to Betaferon treatment is associated with EDSS change (Yes or No)
12 months, 24 months
Disability progressionQuality of life (reported by participants)Adherence to Betaferon treatment is associated with utilities of treatment, recorded by the EQ-5D quality of life questionnaire (Yes or No)
Up to 24 months
Quality of life (reported by participants)
Who could take part
Relapsing MS · 18 and over
Inclusion Criteria: * Patients aged ≥ 18 years with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome * Patients on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician * Patients using or willing to use the BETACONNECT autoinjector for Betaferon application * Written informed consent Exclusion Criteria: * Patients receiving any other disease modifying drug * Contraindications of Betaferon described in the Summary of Product Characteristics * Patients participating in any other clinical or non-interventional study, evaluating MS therapy
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
Papers
Loading reviews and guidelines…
Related trials
- TWINS
Phase 3 · Not yet recruiting
Still running
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumar…
Recruiting
Still running
- Full Responders
Phase 4 · Stopped early
Stopped early
- A Study to Learn More About The Safety of Diroximel Fumar…
Running, not recruiting
Still running
- Study to Investigate Pregnancy Outcomes in Female Partici…
Completed
Result in a paper, not read yet
- 105MS306
Phase 3 · Running, not recruiting
Still running
History
Started
Sept 2015
Main results due
Oct 2019
Finished
Jan 2020
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error